Implementing unequal randomization in clinical trials with heterogeneous treatment costs. (3rd May 2019)

• Record Type: Journal Article
• Authors: Sverdlov, Oleksandr; Ryeznik, Yevgen
• Is Part Of: Statistics in medicine. Volume 38:Number 16(2019)
• Page Start: 2905
• Page End: 2927
• Publication Date: 2019-05-03
• Subjects: allocation ratio preserving randomization procedures -- heterogeneous costs -- multi‐arm clinical trials -- randomization‐based inference -- unequal allocation; Medical statistics -- Periodicals; Statistique médicale -- Périodiques; Statistiques médicales -- Périodiques; 610.727
• DOI: 10.1002/sim.8160
• Languages: English
• ISSNs: 0277-6715

Abstract

Abstract : Equal randomization has been a popular choice in clinical trial practice. However, in trials with heterogeneous variances and/or variable treatment costs, as well as in settings where maximization of every trial participant's benefit is an important design consideration, optimal allocation proportions may be unequal across study treatment arms. In this paper, we investigate optimal allocation designs minimizing study cost under statistical efficiency constraints for parallel group clinical trials comparing several investigational treatments against the control. We show theoretically that equal allocation designs may be suboptimal, and unequal allocation designs can provide higher statistical power for the same budget or result in a smaller cost for the same level of power. We also show how optimal allocation can be implemented in practice by means of restricted randomization procedures and how to perform statistical inference following these procedures, using invoked population‐based or randomization‐based approaches. Our results provide further support to some previous findings in the literature that unequal randomization designs can be cost efficient and can be successfully implemented in practice. We conclude that the choice of the target allocation, the randomization procedure, and the statistical methodology for data analysis is an essential component in ensuring valid, powerful, and robust clinical trial results.